title: Intravenous iron-containing products: EMA procrastination.
abstract: A European reassessment has led to identical changes in the summaries of product characteristics (SPCs) for all intravenous iron-containing products: the risk of serious adverse effects is now highlighted, underlining the fact that intravenous iron-containing products should only be used when the benefits clearly outweigh the harms. Unfortunately, iron dextran still remains on the market despite a higher risk of hypersensitivity reactions than with iron sucrose.
mesh_terms: D005060:Europe; D006801:Humans; D007275:Injections, Intravenous; D007505:Iron-Dextran Complex / Q000009:adverse effects*
chemical_list: D007505:Iron-Dextran Complex